CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma

Journal of Gastroenterology

Volumn 45, Issue 8, 2010, Pages 896-902

  Shimada, Mitsuo ^a   Sugimoto, Koji ^a   Iwahashi, Shuichi ^a   Utsunomiya, Tohru ^a   Morine, Yuji ^a   Imura, Satoru ^a   Ikemoto, Tetsuya ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Hypoxia inducible factor 1 ; Intrahepatic metastasis; Liver cancer; Multivariate analysis

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LEUKOCYTE ANTIGEN; PEPTIDE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INTRAHEPATIC BILE DUCT; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 79952011719     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0235-3     Document Type: Article

References (27)

1. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, et al. Theliver cancer study group of Japan report of the 16th follow-up survey of primary liver cancer. Hepatol Res. 2005;32:163-72. (Pubitemid 41070387)
2. Yamamoto M, Ariizumi S. Intrahepatic recurrence after surgeryin patients with intrahepatic cholangiocarcinoma. J Gastroenterol. 2006;2006(41):925-6. (Pubitemid 44594238)
3. Thelen A, Scholz A, Benckert C, Schröder M, Weichert W, Wiedenmann B, et al. Microvessel density correlates with lymphnode metastases and prognosis in hilar cholangiocarcinoma.J Gastroenterol. 2008;43:959-66.
4. Miwa S, Miyagawa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, et al. Predictive factors for intrahepatic cholangiocarcinomarecurrence in the liver following surgery. J Gastroenterol. 2006;41:893-900. (Pubitemid 44594231)
5. Kobayashi A, Miwa S, Nakata T, Miyagawa S. Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma.Br J Surg. 2010;97:56-64.
6. Shimada M, Yamashita Y, Aishima S, Shirabe K, Takenaka K, Sugimachi K. Value of lymph node dissection during resection ofintrahepatic cholangiocarcinoma. Br J Surg. 2001;88:1463-6. (Pubitemid 32989464)
7. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-10. (Pubitemid 46067310)
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-5. (Pubitemid 46067311)
9. Bertrand J, Begaud-Grimaud G, Bessette B, Verdier M, Battu S, Jauberteau MO. Cancer stem cells from human glioma cell lineare resistant to Fas-induced apoptosis. Int J Oncol. 2009;34:717- 27.
10. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, et al. Cancer stem cell analysis and clinical outcome inpatients with glioblastoma multiforme. Clin Cancer Res. 2008;14:8205-12.
11. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401. (Pubitemid 39551674)
12. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignanttumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res. 2007;67:3153-61. (Pubitemid 46724852)
13. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120:1444-50. (Pubitemid 46355378)
14. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, et al. CD133 expression is correlated with lymph node metastasisand vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008;98:1389-97. (Pubitemid 351543575)
15. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival incolorectal cancer. Br J Cancer. 2008;99:1285-9.
16. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res. 2009;69:7160-4.
17. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 alpha.Oncogene. 2009;28:3949-59.
18. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastriccancers. Br J Cancer. 2008;99:100-9. (Pubitemid 351920235)
19. Kanamoto M, Yoshizumi T, Ikegami T, Imura S, Morine Y,Ikemoto T, et al. Cholangiolocellular carcinoma containing hepatocellular carcinoma and cholangio cellular carcinoma, extremely rare tumor of the liver: a case report. J Med Investig.2008;55:161-5. (Pubitemid 351643609)
20. Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544-56. (Pubitemid 351702738)
21. Liver Cancer Study Group of Japan. Classification of primary liver cancer. 1st English ed. Tokyo: Kanehara; 1997.
22. Becker L, Huang Q, Mashimo H. Immunostaining of Lgr5, anintestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. Scientific World Journal. 2008;8:1168-76.
23. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23. (Pubitemid 47355323)
24. Batmunkh E, Shimada M, Morine Y, Imura S, Kanemura H, Arakawa Y, et al. Expression of hypoxia-inducible factor-1 alpha(HIF-1α) in patients with the gallbladder carcinoma. Int J Clin Oncol. 2010;15(1):59-64.
25. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, Maehara Y. Overexpression of hypoxia-inducible factor 1a and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res. 2006;12:5112-7. (Pubitemid 44453338)
26. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma correlation with poor prognosis with possible regulation. Pancreas. 2008;36:e1-9. (Pubitemid 351440946)
27. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008;62:1212-8. (Pubitemid 351977611)